

#1 BUSINESS HUB FOR PHARMA COMPANIES IN LATIN AMERICA



GLOBAL SERVICES & INNOVATION
RDC - TRADING - SSC



SUSTAINABLE PRODUCTION
MANUFACTURING - DIAGNOSTIC - R&D

Megalabs



MERCK



iclos



sanofi



24 global
companies



1200
FTEs



USD 700 M
transits



39
factories



+4.000
FTEs



54%
exporters



USD 188 M
exports



Success stories



“From AstraZeneca point of view, the cooperation we get with Uruguay has been a key factor that has enable us to improve our supply chains, access more patients, protect our products, ensure that we achieve everything we set out to do.”

Julian Wann

Global Category Leader of Freight and Logistics, AstraZenca



“Megalabs decided to develop its operations in Uruguay due to its legal certainty, competitive talent and the free zone scheme which provides us with the most convenient regulation and stability for a long-term investment. Another key element is Uruguay’s short distances: the manufacturing site is located less than a mile away from the airport and still very close to the port. This is very important because most of our products are exported through the airport and require temperature control.”

Gianclaudio Broggi

CEO, Megalabs



“A favorable legal framework, high democracy index and one of the best economic climates in the region provide an ideal business environment needed for a multinational company. The country has stable and long-term macroeconomic policies that helps the promotion of foreign capital investment and fosters the free zone scheme. Uruguay’s high standards of living compared to the rest of the region, the availability of competitive and highly skilled human resources as well as customer service orientation are also key for the maintenance and growth of our business in the region.”

Gabriela Brancato

Managing Director, Merck Uruguay